NeoPharm Co (092730.KQ) Osake Kurssi

NeoPharm Co., Ltd. generates revenue through the development, manufacture, and sale of cosmetics, medical, and health products under its own brand names. The company sells ATOPALM products, which include daily care, intensive care, special care, and baby care items, as well as Derma:B products such as foam cleansers, oil cleansers, toners, emulsions, creams, facial masks, BB creams, sun protectors, white watering serums, and anti-aging eye creams. ZEROID products, featuring creams and lotions for skin barrier recovery and hypoallergenic foaming cleansers for atopic and sensitive skin, also contribute to sales. Additionally, NeoPharm provides original equipment manufacturing (OEM) services for skin drugs, supplying these to other companies. The primary buyers of NeoPharm's products are consumers seeking skincare solutions for daily use, sensitive skin conditions, and medical-grade treatments. ATOPALM targets general skincare and baby care markets, while Derma:B appeals to users looking for comprehensive skincare routines including anti-aging and sun protection. ZEROID focuses on individuals with atopic or sensitive skin requiring gentle, hypoallergenic products. OEM services are purchased by other pharmaceutical companies needing skin drug manufacturing capabilities. NeoPharm's product portfolio is structured around four key brands: ATOPALM, Derma:B, ZEROID, and OEM services. ATOPALM and Derma:B cater to broad consumer segments in the cosmetics and skincare industry, with Derma:B offering a wide range of products for various skin concerns. ZEROID serves a specialized segment for sensitive skin care, and OEM services target business-to-business clients in the pharmaceutical sector. The company's revenue streams are thus diversified across consumer-facing brands and B2B manufacturing contracts.